Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

FLX Bio's Series C round brings in $60mm

Executive Summary

FLX Bio Inc. (immuno-oncology) raised $60mm in its Series C round. New investor GV took part, along with returning backers The Column Group, Kleiner Perkins Caufield & Byers, Topspin Partners, and Celgene. Proceeds will support the company's pipeline of regulatory T-cell and tumor myeloid cell modulators, including lead candidate FLX475, an oral CCR4 inhibitor that just entered Phase I for multiple tumor types.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies